tion fraction (OR:1.12; p=0.008) and the in-hospital treatment (fibrinolysis and anticoagulation vs. surgery; OR:11.03, p=0.023) where the only variables that predicted PVT recurrences at follow-up. Conclusions: PVT is a life-threatening entity with a high morbidity and mortality, not only during hospitalization but also at follow-up. In survivors, lower ejection fraction and medical treatment during admission (fibrinolysis or anticoagulation) are the main determinants for the recurrence of PVT. DT after discharge does not provide any benefit compared to OAC, regarding mortality, recurrence or bleeding.
In contrast with the inaccuracy of EuroScore I to predict in-hospital mortality after aortic valve replacement (AVR) in octogenarians, recommendations have been made to consider an alternative therapy in case of a EuroScore I ≥ 20. The performance of the new EuroScore in this population of patients has still to be documented.
Aim: To evaluate the performance of the EuroScore II to predict actual in-hospital mortality (IHM) after conventional surgery of AVR in octogenarian patients. Method: Retrospective study including a consecutive series of 386 octogenarian patients operated on conventionally for calcified aortic stenosis between 2005 and 2012 in one surgical center with no direct access to alternative therapy. EuroScore II was calculated online based on medical data files. The mean endpoint was the occurrence of any death during the hospitalization. Multivariate analysis of IHM and determination of Odd Ratios were based on a logistic regression model. Risk score performance was estimated by c-statistic analysis, Hosmer-Lemeshow test (HLT) and correlation coefficient. Results: Independent determinants of IHM were EuroScore II (p=0.004, OR= 1.11), a past history of atrial fibrillation (p=0.02, OR=2.27) and the necessity to use blood transfusion (p=0.005, OR=3.42). EuroScore II underestimated IHM in this series in whatever operative risk group considered. If relatively discriminating (c-statistic = 0.62), the score calibration was poor: p=0.001 (HLT). Thus, Eu-roScore II was not correlated to IHM (r=0.17).
Conclusion: EuroScore II lacks performance to predict early results after conventional AVR in octogenarian patients. Like with all other risk-scores, the additional consideration of frailty and vulnerability are mandatory to assess operative risk in a geriatric population.
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The long-term outcome of biological or mechanical prostheses for heart valve surgery: a meta-analysis of randomised clinical studies Background: The choice of a mechanical (MP) or biological prostheses (BP) is still not a consensus for patients with heart valve disease. Both prostheses have advantages and limitations depending on the age and clinical situation. The aim of this study was to determine the long-term results of MP or BP. Methods: The methods included a systematic review of the following electronic databases Medline/Pubmed, Central-Cochrane Library, Embase/Elsevier, Scopus, Web of Science, and Lilacs which were conducted by independent researchers. Other journals and manuscript sources were also consulted. The following outcomes were analysed: bleeding, infective endocarditis, valve failure, thromboembolism, valve thrombosis, nonstructural dysfunction, re-operation and mortality rate. We assessed and quantified statistical heterogeneity using Cochran's Q test and the I2 statistic. An analysis for the binary outcomes was performed using the Mantel-Haenszel fixed effect models, or Der Simonian and Laird for random effect models when heterogeneity was observed. We calculated the risk ratios (RR) with 95% confidence intervals (95% CIs). An assessment for publication bias was performed using Egger's linear regression test. Two-sided p-values < 0.05 were considered statistically significant. Results: A total of 6,286 references were identified; 19 were analysed and four were included in qualitative analysis and meta-analysis. In total 1,528 patients formed the basis for meta-analysis. No significant difference was found in the total mortality rate between BP and MP in a follow-up period of 20 years (RR=1.05; CI95%:0.97-1.14; p=0.046). The risk of endocarditis (RR=1.44; CI95%: 1.09-1.90), nonstructural dysfunction (RR=11.78; CI95%: 5.11-27.17) and re-operations (RR=3.60; CI95%: 2.51-5.17) were higher for patients with BP; however, paravalvular leak (RR=0.45; CI95%:0.24-0.85) was higher in patients with MP. There were no statistically significant difference between either BP or MP patients for valve thrombosis (RR=0.66; CI95%:0.11-3.91), thromboembolism (RR=1.16; CI95%: 0.82-1.64) or bleeding (RR=0.76; CI95%: 0.54-1.07).
